Major themes include strategies to reprogram the tumor microenvironment and prevent cancer before it starts New insights from AI-based imaging, B-cell biology and mRNA vaccine technology point to more ...

A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared ...

The University of Texas MD Anderson Cancer Center in Houston launched a clinical collaboration with Pfizer to study the use of immuno-oncology drugs to treat various solid tumors and blood cancers.

A new platform developed by researchers at the University of Texas MD Anderson Cancer Center quickly finds and isolates rare, ...

Cancer-induced nerve injury, a cause of chronic inflammation, may lead to immunotherapy resistance, according to a study published Aug. 20 in Nature. The research was led by teams from Houston-based ...

With classic chemotherapy drugs, you know that you're going to give the chemotherapy and a day or two later, you're going to have side effects. With immunotherapy, the side effects can happen at any ...

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...

Lauren Antrim, MD, of City of Hope Cancer Center Duarte, emphasized the need for more evidence to guide optimal immunotherapy duration and sequencing in in non–small cell lung cancer (NSCLC), ...